Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome–related Kaposi sarcoma
Open Access
- 17 November 2003
- Vol. 98 (11) , 2440-2446
- https://doi.org/10.1002/cncr.11816
Abstract
BACKGROUND: The objective of the current study was to evaluate the impact of highly active antiretroviral therapy (HAART) on clinical characteristics of presentation and the natural history of Kaposi sarcoma (KS) in patients already receiving HAART at the time of KS diagnosis.METHODS: The authors conducted a retrospective cohort study comparing epidemiologic, clinical, and outcome data for 160 patients who were naive to HAART at the time of KS diagnosis (KS‐naive) with the corresponding data for 51 patients already receiving HAART at the time of KS diagnosis (KS‐HAART). The analysis included all patients with a diagnosis of KS since January 1996 within two Italian cohorts of patients with human immunodeficiency virus.RESULTS: Immunologic and virologic status at the time of KS diagnosis were significantly more favorable in the KS‐HAART group than in the KS‐naive group. The frequency of cutaneous involvement was similar in both groups, but cutaneous disease was more indolent among KS‐HAART patients, with 1 anatomic site of involvement in 9 patients (21%) and less than 10 lesions in 26 patients (60%), compared with 16 patients (12%; P = 0.06) and 47 patients (34%; P = 0.01), respectively, in the KS‐naive group. A smaller proportion of KS‐HAART patients presented with visceral disease (24% vs. 39%; P = 0.06); in particular, gastrointestinal tract involvement was significantly less frequent among KS‐HAART patients (14%) compared with KS‐naive patients (28%; P = 0.05). Median survival was not reached in either group, and the 3‐year survival rates of KS‐HAART patients (64%) and KS‐naive patients (78%) were not significantly different.CONCLUSIONS: The data from the current study indicate that KS exhibits a less aggressive presentation in patients already receiving HAART compared with patients who are naive to HAART at KS diagnosis. Natural history and outcome do not appear to be influenced by the initiation of HAART before development of KS. Cancer 2003. © 2003 American Cancer Society.Keywords
This publication has 14 references indexed in Scilit:
- Effect of highly active antiretroviral therapy on survival among HIV‐infected men with Kaposi sarcoma or non‐Hodgkin lymphomaInternational Journal of Cancer, 2002
- New therapies for the treatment of AIDS-related Kaposi sarcomaCurrent Opinion in Oncology, 2000
- Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patientsAIDS, 2000
- Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcomeEuropean Journal Of Cancer, 1999
- HAART Is Effective as Anti–Kaposi's Sarcoma Therapy Only After Remission Has Been Induced by ChemotherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- TIMING OF ANTIBODIES TO HUMAN HERPESVIRUS-8 (HHV-8) AMONG HIV-1 SEROCONVERTERS AND PROGRESSION TO KAPOSI'S SARCOMAJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi??s SarcomaDrug Safety, 1999
- Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposiʼs sarcomaAIDS, 1998
- Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agentsCytokine & Growth Factor Reviews, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958